Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric juvenile psoriatic arthritis study of subcutaneous ustekinumab or guselkumab
NL-OMON59358Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ustekinumab and guselkumab in juvenile psoriatic arthritis (JPsA) (2 cohorts), sponsored by Janssen Pharmaceutical. Started Jun 2023; status: completed.
02
Drugs
ustekinumabguselkumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NL-OMON59358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59358.